Using personal and microbiome features enables accurate glucose response prediction (Cell)
Diabetes News
Tag: microbiome
MicroBiome Therapeutics Receives Positive Response From FDA For Use Of Expedited Regulatory Pathway For Diabetes Drug NM505
NM505 is a proprietary combination of an MBT microbiome modulator and metformin, the most widely prescribed first-line therapy worldwide for Type 2 diabetes. A recently-published, peer-reviewed proof-of-concept clinical study showed that NM505 improves the tolerability of metformin while further reducing blood glucose levels in patients with Type 2 diabetes
Glycosmedia is also available as an App: